Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus: A systematic review and meta- Analysis

Siddharth Singh, Sushil Kumar Garg, Preet Paul Singh, Prasad G Iyer, Hashem B. El-Serag

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Background and aims Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta- Analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BOHGD) in patients with BO. Methods We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and/or BO-HGD in patients with BO. Summary ORs with 95% CIs were estimated. Results We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4% PPI users). On meta- Analysis, PPI use was associated with a 71% reduction in risk of OAC and/or BO-HGD in patients with BO (adjusted OR 0.29; 95% CI 0.12 to 0.79). There was a trend towards a dose- response relationship with PPI use for >2-3 years protective against OAC or BO-HGD (three studies; PPI use >2-3 years vs <2-3 years: OR 0.45 (95% CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4% on H2RAs), and both studies did not show a significant effect. Conclusions Based on meta- Analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.

Original languageEnglish (US)
Pages (from-to)1229-1237
Number of pages9
JournalGut
Volume63
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Barrett Esophagus
Meta-Analysis
Adenocarcinoma
Proton Pump Inhibitors
Acids
Observational Studies
Histamine Receptors
Histamine Antagonists
Risk Reduction Behavior

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus : A systematic review and meta- Analysis. / Singh, Siddharth; Garg, Sushil Kumar; Singh, Preet Paul; Iyer, Prasad G; El-Serag, Hashem B.

In: Gut, Vol. 63, No. 8, 2014, p. 1229-1237.

Research output: Contribution to journalArticle

Singh, Siddharth ; Garg, Sushil Kumar ; Singh, Preet Paul ; Iyer, Prasad G ; El-Serag, Hashem B. / Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus : A systematic review and meta- Analysis. In: Gut. 2014 ; Vol. 63, No. 8. pp. 1229-1237.
@article{07f4a490cc284301ad9579134f1dbace,
title = "Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus: A systematic review and meta- Analysis",
abstract = "Background and aims Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta- Analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BOHGD) in patients with BO. Methods We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and/or BO-HGD in patients with BO. Summary ORs with 95{\%} CIs were estimated. Results We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4{\%} PPI users). On meta- Analysis, PPI use was associated with a 71{\%} reduction in risk of OAC and/or BO-HGD in patients with BO (adjusted OR 0.29; 95{\%} CI 0.12 to 0.79). There was a trend towards a dose- response relationship with PPI use for >2-3 years protective against OAC or BO-HGD (three studies; PPI use >2-3 years vs <2-3 years: OR 0.45 (95{\%} CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4{\%} on H2RAs), and both studies did not show a significant effect. Conclusions Based on meta- Analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.",
author = "Siddharth Singh and Garg, {Sushil Kumar} and Singh, {Preet Paul} and Iyer, {Prasad G} and El-Serag, {Hashem B.}",
year = "2014",
doi = "10.1136/gutjnl-2013-305997",
language = "English (US)",
volume = "63",
pages = "1229--1237",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus

T2 - A systematic review and meta- Analysis

AU - Singh, Siddharth

AU - Garg, Sushil Kumar

AU - Singh, Preet Paul

AU - Iyer, Prasad G

AU - El-Serag, Hashem B.

PY - 2014

Y1 - 2014

N2 - Background and aims Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta- Analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BOHGD) in patients with BO. Methods We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and/or BO-HGD in patients with BO. Summary ORs with 95% CIs were estimated. Results We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4% PPI users). On meta- Analysis, PPI use was associated with a 71% reduction in risk of OAC and/or BO-HGD in patients with BO (adjusted OR 0.29; 95% CI 0.12 to 0.79). There was a trend towards a dose- response relationship with PPI use for >2-3 years protective against OAC or BO-HGD (three studies; PPI use >2-3 years vs <2-3 years: OR 0.45 (95% CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4% on H2RAs), and both studies did not show a significant effect. Conclusions Based on meta- Analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.

AB - Background and aims Acid-suppressive medications, particularly proton pump inhibitors (PPIs), may decrease the risk of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO). We performed a systematic review with meta- Analysis of studies evaluating the association between acid-suppressive medications (PPIs and histamine receptor antagonists (H2RAs)) and risk of OAC or high-grade dysplasia (BOHGD) in patients with BO. Methods We performed a systematic search of multiple electronic databases and conference proceedings up to June 2013 to identify studies reporting the association between use of acid-suppressive medications and risk of OAC and/or BO-HGD in patients with BO. Summary ORs with 95% CIs were estimated. Results We identified seven observational studies (2813 patients with BO, 317 cases of OAC or BO-HGD, 84.4% PPI users). On meta- Analysis, PPI use was associated with a 71% reduction in risk of OAC and/or BO-HGD in patients with BO (adjusted OR 0.29; 95% CI 0.12 to 0.79). There was a trend towards a dose- response relationship with PPI use for >2-3 years protective against OAC or BO-HGD (three studies; PPI use >2-3 years vs <2-3 years: OR 0.45 (95% CI 0.19 to 1.06) vs 1.09 (0.47 to 2.56)). Considerable heterogeneity was observed. Two studies reported the association between H2RA use and risk of OAC and/or BO-HGD (1352 patients with BO, 156 cases of OAC, 25.4% on H2RAs), and both studies did not show a significant effect. Conclusions Based on meta- Analysis of observational studies, the use of PPIs is associated with a decreased risk of OAC and/or BO-HGD in patients with BO. None of the studies showed an increased risk of OAC. PPI use should be considered in BO, and chemopreventive trials of PPIs in patients with BO are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84904039736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904039736&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2013-305997

DO - 10.1136/gutjnl-2013-305997

M3 - Article

C2 - 24221456

AN - SCOPUS:84904039736

VL - 63

SP - 1229

EP - 1237

JO - Gut

JF - Gut

SN - 0017-5749

IS - 8

ER -